Inclear

Description

The product is identified by SPL code 34089-3. It is presented as a white to off-white, round, biconvex tablet, which is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for use in patients as determined by the prescribing healthcare professional. Currently, there are no specific indications or usage details provided.

There are no known teratogenic or nonteratogenic effects associated with this drug. Healthcare professionals should consider the absence of these effects when evaluating treatment options for their patients.

Dosage and Administration

The product is intended for external use only. Healthcare professionals should ensure that the medication is applied exclusively to the affected area of the skin. Prior to application, the area should be cleaned and dried thoroughly.

The recommended dosage and frequency of administration will depend on the specific condition being treated. It is essential to follow the prescribed dosing regimen, which may vary based on individual patient needs and response to therapy.

Healthcare professionals should instruct patients to apply the medication as directed, avoiding contact with eyes, mucous membranes, and open wounds. If the condition does not improve or worsens after the recommended treatment period, patients should be advised to consult their healthcare provider for further evaluation and management.

Proper storage conditions should be maintained to ensure the integrity of the product, and any unused medication should be disposed of according to local regulations.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

Healthcare professionals should advise patients to discontinue use of the product and seek consultation with a dermatologist or gynecologist if any of the following signs or symptoms occur: rash, swelling, itching, or irritation during application.

It is particularly important to monitor for these reactions if they manifest in conjunction with exposure to direct sunlight on the treated area.

Additionally, the product is contraindicated for use on areas affected by wounds, eczema, or dermatitis. Careful assessment of the patient's skin condition prior to application is recommended to prevent adverse reactions.

Side Effects

Patients should be advised to discontinue use of the product and consult with a dermatologist or gynecologist if they experience any of the following signs or symptoms: rash, swelling, itching, or irritation during use. Additionally, if any of these symptoms occur on the applied area upon exposure to direct sunlight, patients should seek medical advice promptly.

The product is contraindicated for use in areas affected by wounds, eczema, or dermatitis. It is essential for patients to be aware of these warnings to prevent potential adverse reactions and ensure safe usage.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified for this product. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Inclear (glycerin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. It is essential to ensure that the medication is stored safely to prevent accidental ingestion or misuse.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information regarding the use of INCLEAR - glycerin gel during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this product to pregnant patients. Given the absence of established risk categories or known fetal impacts, it is advisable to weigh the potential benefits against any unknown risks when treating women of childbearing potential. Further studies may be necessary to elucidate the safety profile of this product in pregnant individuals.

Lactation

There is no specific information available regarding the use of this drug in lactating mothers or any lactation considerations. Consequently, healthcare professionals should exercise caution when prescribing this medication to nursing mothers, as the effects on breastfed infants are not established. It is advisable to weigh the potential benefits against any unknown risks when considering treatment options for lactating patients.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide further management and treatment options.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the provided text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion or misuse. It is important for patients to understand the potential risks associated with improper access to the medication by young children. Providers should encourage patients to store the medication in a secure location and to be vigilant about monitoring its use.

Storage and Handling

The product is supplied in a manner that ensures safety and efficacy. It is essential to keep the product out of reach of children to prevent accidental ingestion or misuse. Prior to opening the package, healthcare professionals are advised to wash their hands thoroughly to maintain hygiene and prevent contamination. This product is intended for external use only, and appropriate handling practices should be observed to ensure its safe application.

Additional Clinical Information

The product is administered via the vaginal route. Clinicians should advise patients to keep the product out of reach of children and to wash their hands before opening the package. Patients are instructed to apply a suitable amount of the product, massage it in, and rinse it thoroughly.

Patients should be counseled to discontinue use and consult a dermatologist or gynecologist if they experience any signs or symptoms such as rash, swelling, itching, or irritation during use, especially if these symptoms occur in the presence of direct sunlight. The product should not be applied to wounds, eczema, or dermatitis, and is intended for external use only.

Drug Information (PDF)

This file contains official product information for Inclear, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)